- Home
- NODK vs SGMT Comparison
NODK vs SGMT Comparison
Compare NODK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NODK | SGMT |
|---|---|---|
| Founded | 1946 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.8M | 238.7M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NODK | SGMT |
|---|---|---|
| Price | $14.29 | $6.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.71 |
| AVG Volume (30 Days) | 13.5K | ★ 523.7K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $297,973,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $126.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.01 | $1.73 |
| 52 Week High | $17.06 | $11.41 |
Technical Indicators
Market Signals| Indicator | NODK | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 70.95 | 37.23 |
| Support Level | $13.31 | $5.95 |
| Resistance Level | $14.08 | $6.52 |
| Average True Range (ATR) | 0.39 | 0.38 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 100.00 | 22.04 |
Price Performance
Historical ComparisonAbout NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.